Search

Displaying results 311 - 320 of 1723 in total
  1. Drug

    Diclofenac

    go.drugbank.com/drugs/DB00586
    ApprovedInvestigationalVet approved

    Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).[L7360]

    Mixtures: DICLOVITH-B-FRT, VITAX-FLA
  2. Drug

    Petrolatum

    go.drugbank.com/drugs/DB11058
    ApprovedInvestigational

    A colloidal system of semisolid hydrocarbons obtained from petroleum. It is used as an ointment base, topical protectant, and lubricant.

  3. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health.

  4. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

  5. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  6. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA

  7. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII or antihemophilic factor. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associa...

  8. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  9. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

  10. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557].